Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 14/20 | 0.64 |
| ▸ | BCL2 | P10415 | 11/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 10/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3823164 | 0.85 | BCL2L1 (0.61) | BCL2L1BCL2MCL1MAPTPOLB | |
| SCHEMBL3821370 | 0.83 | MAPT (0.71) | MAPTPOLBPKMTDP1SMN1; SMN2 | |
| SCHEMBL10222787 | 0.82 | BCL2L1 (0.58) | BCL2L1BCL2MCL1MAPTALDH1A1 | |
| SCHEMBL10222702 | 0.82 | BCL2L1 (0.93) | BCL2L1BCL2MCL1 | |
| SCHEMBL29793079 | 0.82 | BCL2L1 (0.93) | BCL2L1BCL2MCL1 | |
| SCHEMBL26681751 | 0.81 | CA2 (0.48) | BCL2L1BCL2MCL1MAPTSMN1; SMN2 | |
| SCHEMBL29793252 | 0.81 | CA2 (0.48) | BCL2L1BCL2MCL1MAPTSMN1; SMN2 | |
| SCHEMBL27202085 | 0.81 | BCL2L1 (0.59) | BCL2L1BCL2MCL1 | |
| SCHEMBL17555037 | 0.81 | BCL2L1 (0.65) | BCL2L1BCL2MCL1MAPTPOLB | |
| SCHEMBL3823485 | 0.81 | MAPT (0.67) | MAPTPOLBPKMTDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-116829524-A | Method for alkylating acidic functional groups | 中外制药株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-110746355-B | Phenylpyrazole compound, pharmaceutical composition, and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022149618-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | 中外製薬株式会社 | 2022-07-14 | — | — | WO | disclosed |
| CN-110746355-A | Phenylpyrazole compound, pharmaceutical composition, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2020-02-04 | — | — | CN | disclosed |
| EP-1763509-B1 | ALPHA-HELICAL MIMETICS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2018-02-21 | — | — | EP | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| WO-2006002474-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-12 | — | — | WO | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885MCL1 14/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885BCL2 3/4885MCL1 11/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885MCL1 14/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | BCL2L1 20/4885BCL2 4/4885MCL1 22/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | BCL2L1 650/4885BCL2 131/4885MCL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.